120 related articles for article (PubMed ID: 29638149)
1. Masitinib in treatment of pancreatic cancer.
Waheed A; Purvey S; Saif MW
Expert Opin Pharmacother; 2018 May; 19(7):759-764. PubMed ID: 29638149
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of masitinib for treating systemic mastocytosis.
Laforgia M; Marech I; Nardulli P; Calabrò C; Gadaleta CD; Ranieri G
Expert Opin Pharmacother; 2019 Sep; 20(13):1539-1550. PubMed ID: 31381378
[No Abstract] [Full Text] [Related]
3. Masitinib for the treatment of mild to moderate Alzheimer's disease.
Folch J; Petrov D; Ettcheto M; Pedrós I; Abad S; Beas-Zarate C; Lazarowski A; Marin M; Olloquequi J; Auladell C; Camins A
Expert Rev Neurother; 2015 Jun; 15(6):587-96. PubMed ID: 25961655
[TBL] [Abstract][Full Text] [Related]
4. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
5. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Dubreuil P; Letard S; Ciufolini M; Gros L; Humbert M; Castéran N; Borge L; Hajem B; Lermet A; Sippl W; Voisset E; Arock M; Auclair C; Leventhal PS; Mansfield CD; Moussy A; Hermine O
PLoS One; 2009 Sep; 4(9):e7258. PubMed ID: 19789626
[TBL] [Abstract][Full Text] [Related]
6. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
7. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.
Prosvicova J; Lukesova S; Kopecky J; Grim J; Papik Z; Kolarova R; Navratilova B; Dubreuil P; Agopian J; Mansfield C; Moussy A; Hermine O
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):695-7. PubMed ID: 26725706
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
Lee-Fowler TM; Guntur V; Dodam J; Cohn LA; DeClue AE; Reinero CR
Int Arch Allergy Immunol; 2012; 158(4):369-74. PubMed ID: 22487554
[TBL] [Abstract][Full Text] [Related]
10. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis.
Trias E; Ibarburu S; Barreto-Núñez R; Babdor J; Maciel TT; Guillo M; Gros L; Dubreuil P; Díaz-Amarilla P; Cassina P; Martínez-Palma L; Moura IC; Beckman JS; Hermine O; Barbeito L
J Neuroinflammation; 2016 Jul; 13(1):177. PubMed ID: 27400786
[TBL] [Abstract][Full Text] [Related]
11. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
[TBL] [Abstract][Full Text] [Related]
12. Masitinib for the treatment of Alzheimer's disease.
Ettcheto M; Cano A; Sanchez-López E; Verdaguer E; Folch J; Auladell C; Camins A
Neurodegener Dis Manag; 2021 Aug; 11(4):263-276. PubMed ID: 34412534
[TBL] [Abstract][Full Text] [Related]
13. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
15. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
Humbert M; de Blay F; Garcia G; Prud'homme A; Leroyer C; Magnan A; Tunon-de-Lara JM; Pison C; Aubier M; Charpin D; Vachier I; Purohit A; Gineste P; Bader T; Moussy A; Hermine O; Chanez P
Allergy; 2009 Aug; 64(8):1194-201. PubMed ID: 19614621
[TBL] [Abstract][Full Text] [Related]
16. Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma.
Rudloff U
Expert Opin Emerg Drugs; 2022 Sep; 27(3):345-368. PubMed ID: 36250721
[TBL] [Abstract][Full Text] [Related]
17. Emerging protein kinase inhibitors for treating pancreatic cancer.
Furuse J; Nagashima F
Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
[TBL] [Abstract][Full Text] [Related]
19. Emerging cell-cycle inhibitors for pancreatic cancer therapy.
Bayraktar S; Rocha Lima CM
Expert Opin Emerg Drugs; 2012 Dec; 17(4):571-82. PubMed ID: 23126234
[TBL] [Abstract][Full Text] [Related]
20. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
